Results 21 to 30 of about 32,821 (278)

Cell-type specific potent Wnt signaling blockade by bispecific antibody. [PDF]

, 2018
Cell signaling pathways are often shared between normal and diseased cells. How to achieve cell type-specific, potent inhibition of signaling pathways is a major challenge with implications for therapeutic development.
Bidlingmaier, Scott, Ha, Kevin D, Lee, Nam-Kyung, Liu, Bin, Sherbenou, Daniel W, Su, Yang, Zhang, Yafeng   +6 more
core   +2 more sources

Selective engagement of FcγRIV by a M2e-specific single domain antibody construct protects against influenza A virus infection [PDF]

, 2019
Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as well as pandemic influenza A.
Ballegeer, Marlies, Creytens, Sarah, De Vlieger, Dorien, Hengel, Hartmut, Hoffmann, Katja, Nerinckx, Wim, Remaut, Han, Saelens, Xavier, Schepens, Bert, Van Hoecke, Lien, Van Molle, Inge   +10 more
core   +2 more sources

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Fenn, Sebastian, Gassner, Christian, Griese, Julia J., Hopfner, Karl-Peter, Imhof-Jung, Sabine, Kettenberger, Hubert, Klein, Christian, Moelleken, Joerg, Regula, Joerg Thomas, Schaefer, Wolfgang, Schiller, Christian B., Thomas, Markus   +12 more
core   +3 more sources

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells

Antibodies, 2013
Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials.
Luis Alvarez-Vallina, Laura Sanz, Natalia Nuñez-Prado, Marta Compte   +3 more
doaj   +1 more source

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Cell Discovery, 2022
The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs).
Yingdan Wang, Xiang Zhang, Yunping Ma, Yanqun Wang, Wuqiang Zhan, Qinwen Zheng, Meng Zhang, Ping Ji, Mei Liu, Qianying Liu, Tingting Sun, Tongyu Zhu, Yumei Wen, Lei Sun, Jincun Zhao, Fan Wu, Zhenguo Chen, Jinghe Huang   +17 more
doaj   +1 more source

Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

mAbs, 2021
Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging.
Pallavi Bhatta, Kevin D. Whale, Amy K. Sawtell, Clare L. Thompson, Stephen E. Rapecki, David A. Cook, Breda M. Twomey, Milena Mennecozzi, Laura E. Starkie, Emily M. C. Barry, Shirley J. Peters, Ahmad M. Kamal, Helene M. Finney   +12 more
doaj   +1 more source

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

Emerging Antibodies in Cancer Therapy

Advanced NanoBiomed Research, 2023
Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj   +1 more source